摘要
【目的】探讨糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、前列腺特异性抗原(PSA)、甲胎蛋白(AFP)、游离前列腺特异性抗原(f-PSA)六种肿瘤标志物联合检测对卵巢癌的诊断价值。【方法】用酶联免疫分析方法联合检测30例良性卵巢疾病患者,22例卵巢癌患者和26例健康对照者,分析各指标组间的差异和单项、联合检测对卵巢癌患者的检出率。【结果】卵巢癌组单项阳性率由高至低依次为:CA125 63.63%(14/22)、CA19-9 54.54%(12/22)、CEA 31.81%(7/22)、AFP 13.63%(3/22)f、-PSA 9.09%(2/22)、PSA 0%(0/22)。经卡方检验,良性卵巢疾病组和卵巢癌组有显著性差异。去除PSA后,采用五指标联合检测,敏感性为90.91%,特异性为73.33%,诊断效率达80.77%。【结论】肿瘤标志物CA19-9、CA125、CEA、AFPf、-PSA联合检测可提高卵巢癌的诊断效率,对其早期诊断有一定价值。
[Objective]To inquire into the diagnostic value of allied detection of six tumor markers： CA125, CA19-9, CEA , PSA , AFP and f-PSA , in ovarian cancer patients. [Methods]ELISA was used to detect thirty patients with sub-clinical symptoms, twenty-two with ovarian cancer and twenty-six healthy controls. The statistic difference was analysed and the positive rates of mono-detection and allied detection were calculated. [Results]Tbe mono-detection positive rate in ovarian cancer group was CA125 63.63 % （ 14/22 ）, CA19-9 54.54 % （ 12/22 ）, CEA 31.81% （7/22）, AFP 13. 63% （3/22）, f-PSA 9.09% （2/22）, PSA 0% （0/22）, respectively. There was statistic difference between sub-clinical symptoms group and ovarian cancer group. When the markers were allied to diagnose the ovarian cancer, the sensitivity, specificity and the efficiency were 90. 91%, 73.33 %, and 80. 77 % respectively. [Conclusion]The tumor markers allied detections of CA19-9, CA125, CEA, AFP, f-PSA could improve the diagnosis of ovarian cancer and have great value to earlier diagnosis.
出处
《医学临床研究》
CAS
2006年第4期486-487,490,共3页
Journal of Clinical Research
